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20.9 percent for strontium ranelate — are given
both in the Results section and in Figure 2.
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Circulating Angiogenic Factors and Preeclampsia
 
to the editor: 
 





shown that increased levels of soluble fms-like ty-
rosine 1 (sFlt-1) and reduced levels of placental
growth factor (PlGF) predict the development of
preeclampsia, a few weeks before the onset of clin-
ical symptoms. Circulating angiogenic factors pro-
duced by the placenta could therefore be used to
predict preeclampsia. Since vascular endothelial
growth factor (VEGF) levels did not differ signifi-
cantly between the controls and the women who
later had preeclampsia, attention has been focused
on PlGF and sFlt-1 modifications. However, differ-
ences in free VEGF concentrations might have been
underestimated because measurements were per-




Serum samples do not reflect the placental produc-
tion of VEGF, since they are “contaminated” by the
release of VEGF from platelets and other blood
cells during clotting, and it has been recommend-




We agree that prospective longitudinal studies are
needed to assess the relevance of these markers
(sFlt-1 and PlGF) for the prediction of preeclamp-
sia. Such studies should also include VEGF mea-
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We thank Dr. Tsatsaris and col-
leagues for pointing out that low free VEGF con-
centrations may have the potential to predict pre-
eclampsia. We agree that measurements in serum,
rather than plasma, may have reduced our ability
to discriminate between women who subsequent-
ly had preeclampsia and those who did not. Perhaps
even more important is the fact that the minimal
detectable VEGF concentration with the immuno-
assay we used (R&D Systems) was about 5 pg per
milliliter — not much lower than the mean serum
concentration during clinical preeclampsia in the
women in our study (6.4 pg per milliliter). It is like-
ly that plasma VEGF concentrations are even lower,
since the contribution from platelets is not includ-




 reported that in their
study, free VEGF was not detectable in most ma-
ternal plasma specimens, and we have been unable
to detect free VEGF in fresh plasma obtained dur-
ing preeclampsia (unpublished data). Regardless
of whether plasma or serum is used, an assay must
have a sensitivity of 1 pg or less of free VEGF per
milliliter to be clinically useful. Unless such an as-
say is developed, it will be impossible to determine
whether measurements of VEGF in plasma may be
better than serum measurements for the predic-
tion of preeclampsia.
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Risks of Testosterone Replacement
 











 (Jan. 29 issue) assuage the anxiety of physi-
cians who administer testosterone to older men
because the men report andropause, a collection of
ill-defined maladies related to male aging. Their po-
sition in this regard is very disconcerting.
More than 50 years ago, physicians began treat-





then, no standardized definition of this condition
has been developed, no metric defining a therapeu-
tic effect has been created, no randomized con-
trolled studies have been conducted to support the
widespread use of testosterone in men for this con-
dition, and the adverse-event profile of the drug in
this population has not been studied adequately.
The Food and Drug Administration (FDA) has not
approved testosterone for this condition. In addi-
tion, the schemes suggested by Rhoden and Mor-
gentaler and by Snyder for managing the risk of
prostate cancer, a hazard of testosterone exposure
that is of great concern, are untested.
The Women’s Health Initiative advanced our un-
derstanding of the risks and benefits of estrogen





 advises thoughtful, well-designed
research on testosterone in aging men; this should
be supported.
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to the editor: 
 
We wish to address several points
made by Rhoden and Morgentaler and by Snyder,
as highlighted by a recent case. A 59-year-old man
with idiopathic hypogonadism who was receiving
testosterone-replacement therapy was referred be-
cause of a rising prostate-specific antigen (PSA) lev-
el (4.0 ng per milliliter; total testosterone level,
202 ng per deciliter; free testosterone level, 45 pg
per milliliter). Biopsy revealed adenocarcinoma of
the prostate (Gleason grade, 6). A radical retropu-
bic prostatectomy was performed. Pathological
examination revealed extensive organ-confined
adenocarcinoma (Gleason grade, 6; tumor–node–
metastasis stage, T2N0Mx). Three and six months
postoperatively, PSA was undetectable, and without
testosterone replacement, his testosterone levels
were 410 and 487 ng per deciliter, respectively.
Because prostate cancer can suppress the hypo-





 we propose that adenocar-
cinoma of the prostate be considered in the differ-
ential diagnosis of hypogonadism. Furthermore,
because removal of the prostate may lead to nor-
malization of testosterone levels in hypogonadal
men who have previously received testosterone-
replacement therapy, we recommend measurement
of testosterone before therapy is reinstated after
surgery.
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to the editor: 
 
In reviewing the risks of testoster-
one replacement in older men, Rhoden and Mor-
gentaler did not mention a safety concern specific
to transdermal gels and creams: the transfer of tes-
tosterone from the patient to a partner or child
through skin-to-skin contact. Reports from France
describe women who had supraphysiologic tes-
tosterone levels, signs of hirsutism, or both after
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